Please login or register first to view this content.
Oncology Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
- Bladder, kidney, and other urologic cancers
- Bone and connective tissue cancer
- Breast cancer
- CNS cancer
- Colorectal and other GI cancers
- Cytoprotective and supportive care agents
- Eye cancer
- Gynecologic cancer
- Head and neck cancer
- Kaposi’s sarcoma
- Leukemias, lymphomas, and other hematologic cancers
- Melanoma and other skin cancers
- Pancreatic, thyroid, and other endocrine cancers
- Prostate and other male cancers
- Respiratory and thoracic cancers
NEWS & FEATURES
FDA Denies Accelerated Approval of Keytruda Plus Lenvima for Unresectable HCC
USPSTF Advises Annual Low-Dose CT Lung Screening for High-Risk Individuals
Physician Overlooks MRI, Then Claims Chiropractor Patient Should Have Read It
Trial Evaluating Pracinostat in AML Patients Unfit for Intensive Chemotherapy Discontinued
Bavencio Approved for First-Line Urothelial Carcinoma Maintenance Treatment
Phesgo Approval Allows for Faster Administration of Pertuzumab and Trastuzumab
Keytruda Approved as First-Line Treatment of MSI-H or dMMR Colorectal Cancer
New Guideline Issued for Managing Advanced Prostate Cancer
Keytruda Approved for Cutaneous Squamous Cell Carcinoma
Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Vitamin D May Cut Colitis Risk for Immune Checkpoint Inhibitors
Crysvita Approved for Treatment of Tumor-Induced Osteomalacia
Tazverik Granted Accelerated Approval for Follicular Lymphoma
FDA Approves Keytruda for Tumor Mutational Burden-High Cancer
Mylotarg Indication Expanded to Include Newly-Diagnosed Pediatric AML
Zepzelca Approved for Metastatic Small Cell Lung Cancer
Gardasil 9 Approved to Prevent Certain HPV-Related Head and Neck Cancers
FDA Grants Orphan Drug Status to Berubicin for Malignant Gliomas
